Medscape | Biologics Projected to Transform Uveitis Treatment Medscape These include the anti-CD20 inhibitors rituximab and ocrelizumab, the anti-TNF inhibitors certolizumab and golimumab, the interleukin-6 inhibitor tocilizumab, the interleukin-1 inhibitor canakinumab, the anti-CTLA-4 inhibitor abatacept, and the small ... |
